Cronos Group (NASDAQ:CRON) Announces Earnings Results, Meets Estimates

Cronos Group (NASDAQ:CRON) issued its quarterly earnings results on Monday. The company reported $0.01 EPS for the quarter, meeting analysts’ consensus estimates of $0.01, Zacks reports. The firm had revenue of $58.97 million during the quarter, compared to the consensus estimate of $42.20 million. Cronos Group had a negative return on equity of 1.41% and a negative net margin of 1.14%.

Here are the key takeaways from Cronos Group’s conference call:

• Record financial performance: Cronos reported Q1 net revenue of CAD 45.2M (+40% YoY) and record gross profit of CAD 19.2M (+39% YoY) with adjusted EBITDA of CAD 5.1M, the second-highest in company history.
• Spinach market leadership: The Spinach brand captured #1 positions in vapes (9.8% total vape share and 11.1% cartridge share) and edibles (20.8% total, gummies 22.7%), with PUFFERZ reaching #2 in all-in-one vapes just four months after launch.
• Strong international momentum and M&A: Cronos Israel grew 53% YoY (ninth consecutive record quarter) and other international markets grew 97% YoY, and management expects the CanAdelaar acquisition (Netherlands market leader) to close in summer 2026 to scale its European footprint.
• Robust balance sheet and capital return: The company has no debt, CAD 822M in cash and equivalents, and the board authorized a renewed CAD 50M share repurchase program to deploy capital across growth, buybacks, and M&A.
• Cost and timing pressures: Operating expenses rose to CAD 20.5M (up CAD 3.3M YoY) partly due to CanAdelaar transaction costs, cash decreased CAD 10M in the quarter after CAD 17M of repurchases, and the CanAdelaar long-stop date was extended as a precaution, introducing execution and timing risk.

Cronos Group Stock Down 0.2%

NASDAQ:CRON traded down $0.01 during trading hours on Wednesday, reaching $2.77. 738,540 shares of the stock were exchanged, compared to its average volume of 1,423,412. The firm has a 50 day simple moving average of $2.59 and a 200-day simple moving average of $2.61. Cronos Group has a 52 week low of $1.84 and a 52 week high of $3.43. The stock has a market capitalization of $1.04 billion, a P/E ratio of 276.78 and a beta of 0.87.

Analysts Set New Price Targets

A number of brokerages recently commented on CRON. Wall Street Zen raised Cronos Group from a “sell” rating to a “hold” rating in a report on Sunday, March 8th. Canaccord Genuity Group began coverage on Cronos Group in a report on Tuesday, January 27th. They issued a “buy” rating for the company. Weiss Ratings downgraded Cronos Group from a “hold (c)” rating to a “sell (d+)” rating in a report on Monday, March 2nd. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $2.30 target price on shares of Cronos Group in a report on Wednesday, January 14th. Finally, TD Securities reaffirmed a “buy” rating on shares of Cronos Group in a report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $2.30.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Virtu Financial LLC lifted its holdings in Cronos Group by 10.4% during the 4th quarter. Virtu Financial LLC now owns 52,852 shares of the company’s stock worth $139,000 after buying an additional 4,990 shares during the last quarter. Pillsbury Lake Capital LLC bought a new position in Cronos Group during the 4th quarter worth approximately $4,837,000. Jump Financial LLC bought a new stake in shares of Cronos Group in the 4th quarter worth approximately $42,000. Headlands Technologies LLC lifted its holdings in shares of Cronos Group by 12.5% in the 4th quarter. Headlands Technologies LLC now owns 63,097 shares of the company’s stock worth $166,000 after purchasing an additional 6,998 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Cronos Group in the 4th quarter worth approximately $196,000. Institutional investors own 8.71% of the company’s stock.

Cronos Group Company Profile

Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.

The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.